PMID- 23877328
OWN - NLM
STAT- MEDLINE
DCOM- 20140404
LR  - 20240213
IS  - 1873-4626 (Electronic)
IS  - 1091-255X (Linking)
VI  - 17
IP  - 9
DP  - 2013 Sep
TI  - Dendritic cell-based immunotherapy targeting synthesized peptides for advanced 
      biliary tract cancer.
PG  - 1609-17
LID - 10.1007/s11605-013-2286-2 [doi]
AB  - BACKGROUND: The aim of this retrospective study was to clarify the safety and 
      efficacy of dendritic cell (DC)-based immunotherapy targeting synthesized 
      peptides, Wilms tumor 1 (WT1) and Mucin 1, cell surface associated (MUC1) for 
      biliary tract cancers (BTCs). METHODS: Sixty-five patients who had nonresectable, 
      recurrent, or metastatic BTCs and received the DC-based immunotherapy were 
      selected for the study. DCs were pulsed with WT1 and/or MUC1. The adverse events 
      (AEs) and clinical responses were examined. RESULTS: No serious treatment-related 
      AEs were observed. Median survival time (MST) from diagnosis and from the first 
      vaccination was 18.5 and 7.2 months, respectively. By multivariate Cox 
      proportional hazard analysis, the significant independent factors were found to 
      be (1) combined chemotherapy, (2) albumin level >/=4.0 g/dL before vaccination, (3) 
      C-reactive protein level <0.5 mg/dL before vaccination, and (4) fever after 
      vaccination. The MST from the first vaccination with or without chemotherapy was 
      8.2 and 5.3 months, respectively (P = 0.016), and MST for the patients with 
      prognostic nutritional index >/=40 and <40 was 8.1 and 5.0 months, respectively 
      (P = 0.023). CONCLUSIONS: Although a small uncontrolled nonrandomized study, 
      DC-based immunotherapy for BTCs was safe and produced a clinical response for the 
      patients who underwent chemotherapy and maintained a good nutrition status.
FAU - Kobayashi, Masanori
AU  - Kobayashi M
AD  - Seren Clinic Nagoya, Isokai, 4-14-2 Sakae, Naka-ku, Nagoya, 460-0008, Japan. 
      m.kobayashi@serenclinic.or.jp
FAU - Sakabe, Tomoyo
AU  - Sakabe T
FAU - Abe, Hirofumi
AU  - Abe H
FAU - Tanii, Mitsugu
AU  - Tanii M
FAU - Takahashi, Hidenori
AU  - Takahashi H
FAU - Chiba, Asako
AU  - Chiba A
FAU - Yanagida, Eri
AU  - Yanagida E
FAU - Shibamoto, Yuta
AU  - Shibamoto Y
FAU - Ogasawara, Masahiro
AU  - Ogasawara M
FAU - Tsujitani, Shun-ichi
AU  - Tsujitani S
FAU - Koido, Shigeo
AU  - Koido S
FAU - Nagai, Kazuhiro
AU  - Nagai K
FAU - Shimodaira, Shigetaka
AU  - Shimodaira S
FAU - Okamoto, Masato
AU  - Okamoto M
FAU - Yonemitsu, Yoshikazu
AU  - Yonemitsu Y
FAU - Suzuki, Noboru
AU  - Suzuki N
FAU - Nagaya, Masaki
AU  - Nagaya M
CN  - DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT)
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20130720
PL  - Netherlands
TA  - J Gastrointest Surg
JT  - Journal of gastrointestinal surgery : official journal of the Society for Surgery 
      of the Alimentary Tract
JID - 9706084
RN  - 0 (Cancer Vaccines)
RN  - 0 (MUC1 protein, human)
RN  - 0 (Mucin-1)
RN  - 0 (WT1 Proteins)
RN  - 0 (WT1 protein, human)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Bile Duct Neoplasms/immunology/mortality/therapy
MH  - Bile Ducts, Extrahepatic
MH  - Bile Ducts, Intrahepatic
MH  - Biliary Tract Neoplasms/immunology/mortality/*therapy
MH  - Cancer Vaccines/*therapeutic use
MH  - Cholangiocarcinoma/immunology/mortality/therapy
MH  - Dendritic Cells/*immunology
MH  - Female
MH  - Gallbladder Neoplasms/immunology/mortality/therapy
MH  - Humans
MH  - Immunotherapy, Active/*methods
MH  - Male
MH  - Middle Aged
MH  - Mucin-1/*immunology
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - WT1 Proteins/*immunology
EDAT- 2013/07/24 06:00
MHDA- 2014/04/05 06:00
CRDT- 2013/07/24 06:00
PHST- 2013/05/02 00:00 [received]
PHST- 2013/07/05 00:00 [accepted]
PHST- 2013/07/24 06:00 [entrez]
PHST- 2013/07/24 06:00 [pubmed]
PHST- 2014/04/05 06:00 [medline]
AID - S1091-255X(23)04143-4 [pii]
AID - 10.1007/s11605-013-2286-2 [doi]
PST - ppublish
SO  - J Gastrointest Surg. 2013 Sep;17(9):1609-17. doi: 10.1007/s11605-013-2286-2. Epub 
      2013 Jul 20.